TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06235684

Intervention type: OTHER
Intervention: Either newly diagnosed with a RD requiring initiation of therapy OR treatment change at the time of inclusion
Description: During the first year, data related to demographics, lifestyle, laboratory and physical examinations will be collected at baseline, at month 3, at month 12 and in case of unscheduled visit. Questionnaires and standardised voice collection will be collected (optionally) at different time points using the Colive web app. Physical activity and sleep quality will be optionally monitored via a smartwatch that will be provided to interested participants. Biological sample(s) and imaging data will be collected at different time points (baseline; 3 months; 12 months; unscheduled visit). A long-term follow-up (starting from month 12 and up to 4 years after month 12) is foreseen in this study. During the long-term follow-up medical data are collected on a yearly basis, and questionnaires are collected every 6 months.
Study: NCT05290441

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: None involvement
Description: No EGFR involvement
Study: NCT05568030

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psycho-education
Description: One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
Study: NCT05945771

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Grape seed extract
Description: Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Grape seed extract
Description: Acute effect of dietary supplementation with GSE on hemodynamic responses during static exercise and muscle metaboreflex and during cycling exercise.
Study: NCT05223062

Intervention type: OTHER
Intervention: Disease activity in psoriatic arthritis (DAPSA)
Description: DAPSA includes a 68/66 joint count summed with a patient global, patient pain score, and C- reactive protein level. The DAPSA provides a continuous score of arthritis activity and has validated cut points for remission (\< 4) and low disease activity (\< 14).

Intervention type: OTHER
Intervention: Compliance-Questionnaire-Rheumatology (CQR)
Description: The CQR is a self-administered questionnaire that was developed with the aim of correctly identifying patients that were classified as low adherers (taking \<80% of their medication correctly). The four point Likert answering scale ranges from; Definitely don't agree (scored 1) to Definitely agree (scored 4) with lower scores indicating lower levels of adherence. Total score is between 0 and 100.

Intervention type: OTHER
Intervention: The Brief Illness Perception Questionnaire (BIPQ)
Description: The Brief Illness Perception Questionnaire (BIPQ) is a questionnaire that assesses a number of beliefs about illness which are thought to be related to coping and help-seeking behavior. Each item is scored between 0 and 10. Maximum total score is 80. Higher scores represents that the patient has a concerned perception of illness.

Intervention type: OTHER
Intervention: The Beliefs About Medicines Questionnaire (BMQ)
Description: The Beliefs About Medicines Questionnaire (BMQ) is a tool for evaluating people's beliefs about medicines. The BMQ comprises two sections: the BMQ-Specific which assesses representations of medication prescribed for personal use and the BMQ-General which assesses beliefs about medicines in general. It has a total of 18 questions scored with a 5-point Likert scale. Higher scores represent more powerful beliefs.

Intervention type: OTHER
Intervention: Hospital Anxiety and Depression Scale (HADS)
Description: Hospital Anxiety and Depression Scale (HADS) determines the levels of anxiety and depression that a person is experiencing. The HADS is a fourteen item scale that generates: Seven of the items relate to anxiety and seven relate to depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression.

Intervention type: OTHER
Intervention: The Psoriatic Arthritis Quality of Life (PsAQoL)
Description: The Psoriatic Arthritis Quality of Life (PsAQoL) measure is a disease specific patient-reported outcome measure which measures the effect that psoriatic arthritis has on a patient's quality of life. It is a self-administered, 20-item questionnaire that takes about three minutes to complete. The answers are restricted to true or false.A high score on the PsAQoL indicates a lower quality of life. Total score is between 0 and 20.
Study: NCT05962034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 650 mg aspirin (Acetylsalicylic acid)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo capsule
Study: NCT05290441

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: None involvement
Description: No EGFR involvement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: None involvement
Description: No EGFR involvement
Study: NCT05256784

Intervention type: COMBINATION_PRODUCT
Intervention: Natural probiotics
Description: Two of the group members use daily Allium Sativum - garlic, one use Natural honey, and 1 Yogurt. It is verifying the immunity of the organism after 40 days of using natural probitotics.
Study: NCT05596487

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: repetitive standardized patient simulation
Description: In the study, an end-of-life care nursing education program was applied to all students. In the second stage, the standard patient-based practice was performed once with the control group nursing students and twice with the intervention group students. In data collection, an end-of-life care nursing questionnaire, Frommelt attitude scale, positive-negative affect scale, and modified simulation effectiveness tool were used.
Study: NCT05479435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blue Prescription Exercise Program
Description: After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. It will be followed up with the blue prescription program once a week for 12 weeks and will be re-evaluated at the end of the 12th week. Motivation and support will be provided according to the blue prescription philosophy, home exercise program, physical activity selection, obstacles to the activity are discussed, the participant will be asked to determine the appropriate program and keep an activity diary. Throughout the study, the participant will be able to communicate with the physiotherapist by any method (phone, SMS, email).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Based Home Exercise Program
Description: After the evaluation, DM and physical activity training will be given, the benefits of exercise will be explained and these will be given as a brochure. A video exercise program will be given in the format and method desired by the participant. It will be evaluated again at the end of the 12th week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supervised Group Exercise Program
Description: DM and physical activity training will be given after the assessment, the benefits of the exercise will be explained and these will be given as a brochure. Exercises will be done with a physiotherapist for 12 weeks 3 days a week and will be evaluated again at the end of the 12th week.
Study: NCT05000268

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Myofascial Relaxation Exercise
Description: Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Myofascial Relaxation Exercise
Description: Participants will be given telerehabilitation methods, progressive myofascial relaxation techniques and simple posture correction exercises every other day for 2 weeks. The exercises will be performed as follows:~* First, focus on creating tension in the body by contracting all your body muscles and feeling the body tension by holding this tight position for 3-5 seconds. Then relax and relax and focus on feeling the relaxed position of the muscles for 10-15 seconds. Then, the same contraction and relaxation movements will be applied in the feet, legs, hips, waist, chest, shoulders, arms and face areas, respectively. They will be asked to do these exercises in the morning and evening while lying in bed.
Study: NCT05004363

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lokelma Oral Product
Description: Potassium binder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lokelma Oral Product
Description: Potassium binder
Study: NCT05357924

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: robotic-assisted laparoscopy
Description: Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional laparoscopy
Description: Superficial and deep endometriosis resection will be performed in the usual standard fashion. All superficial lesions suspicious for endometriosis (pigmented and nonpigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy will be performed for endometriomas. Additional procedures are performed as needed to completely resect all endometriosis lesions. The fascia of any port ≥10 mm will be reapproximated. Cystoscopy will be performed when deemed appropriate by the surgeon. If bowel resection and re-anastomosis is necessary this will be performed together with a General Surgeon.
Study: NCT05724654

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skin roasted peanuts
Description: Study volunteers will receive daily 60 g of skin roasted peanuts for 16 weeks.
Study: NCT05844592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INV-101
Description: subjects will be randomized 3:1 ratio
Study: NCT04974203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AptameX
Description: DNA aptamer-based test using patient's saliva

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AptameX
Description: DNA aptamer-based test using patient's saliva

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AptameX
Description: DNA aptamer-based test using patient's saliva
Study: NCT06200922

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic physiotherapy
Description: All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic physiotherapy
Description: All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic physiotherapy
Description: All groups will receive the same treatment for 12 weeks, which will include floor muscle training pelvic floor, urge suppression techniques, bladder training and behavioral therapy.
Study: NCT05076214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic exercise in group
Description: The goal with every new week should be making every workout a little bit harder than the week before.~Strength sessions~Week 1- 6: 12-18 repetitions (reps) x 2 set per exercise and muscle 30 seconds (s) rest between exercise Week 7-12: 10-12 reps x 3 set per exercise and muscle 20 s rest between exercises Adding weight with gym equipment or changing body position in the exercises to succeed with the rep scheme and making it harder as the group develop their physical and mental ability.~Conditioning sessions~Week 1- 6: 75 seconds work time x 1 set per exercise 30 seconds of rest between exercises Week 7-12: 50 seconds work time x 2 set per exercise 20 seconds of rest between exercises Mixed sessions~Week 1- 6: 35 s work time per exercise 25 s rest between exercises x 2 rounds Week 7-12: 45 s work time per exercise 15 s rest between exercises x 2 rounds

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Leisure activities in group
Description: The control group will receive leisure activity in a group setting for one hour three times a week for 12 weeks. The sessions will be held at the same weekdays and about the same hours as the exercise group sessions. The same group leaders as in the exercise sessions will participate in leisure sessions and will support the adolescents through reminders and reassurance before and during the sessions to enhance adherence. The sessions will start with a check in on feelings, recent events and difficulties (i.e. supportive listening but not any interventions) followed by non heart rate increasing activities, such as playing games or cards together
Study: NCT06312566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam (BRV) tablet
Description: Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam (BRV) tablet
Description: Study participants will receive multiple-doses of brivaracetam tablet (reference - Treatment A) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam (BRV) dry syrup
Description: Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brivaracetam (BRV) dry syrup
Description: Study participants will receive multiple-doses of brivaracetam dry syrup (test - Treatment B) administered orally.
Study: NCT04693169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 11C-Choline
Description: 1、PSMA137 labeled with \[Al18F\] will be used as a molecular imaging tracer for PET/CT scanning。 2、11C-choline (0.05-0.1mCi/kg) was injected intravenously in a week after the \[Al18F\]PSMA137 PET/CT examination, and imaging of the head and body cadres was performed 20 min after the injection using Philips Gemini TF16 or Siemens Biograph M-CT flow PET/CT
Study: NCT05938504

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ONS_320275
Description: Subjects will consume two packs (165ml/pack) of placebo ONS (ONS_320275) orally daily at any time of day.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ONS_211567
Description: Subjects will consume two packs (165ml/pack) of test ONS (ONS_211567) orally daily at any time of day.
Study: NCT05913505

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: OSC+
Description: The first session of the HRVB intervention will focus on introducing the client to HRVB and calculating the participant's resonance frequency which typically range from 4.5-7 breaths per minute. Participants will first complete a five-minute baseline breathing condition. Following the breathing condition, the participants will complete five conditions for five minutes each. Specifically, each condition will have the person breath at 6, 6.5, 5.5, 5, and 4.5 breaths per minute with a minute break between. Session two will focus on practicing resonance frequency breathing and solidifying the correct resonance frequency for the participant. Additionally, this session will introduce the technique of breathing through pursed lips and abdominal breathing. For sessions three through five, participants will practice resonance frequency breathing and review previous strategies.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: OSC-
Description: During the first week, the baseline will be assessed and resonance frequency. Specifically, during their first intervention session the participants will be told that the goal of the sessions includes decreasing heart rate variability and avoiding slow and steady breathing. The participants will then be asked to choose five strategies to lower their heart rate oscillations. Participants will be told to avoid slow breathing as it causes large heart rate oscillations. For the second session, the therapist will check in with the participant and discuss how the practice went. Participants will then select three strategies that they will practice for three five-minute conditions following a five-minute baseline. Sessions three, four, and five will include three conditions: a five-minute baseline and two strategies of their choice. For each session, the best strategy will be calculated and written on the assignment sheets to be used during the week for their four homework sessions.
Study: NCT05383989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UniVenture Hopelessness manual
Description: Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UniVenture Hopelessness manual
Description: Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Hopelessness (HOP) personality traits on the Substance Use Risk Profile Scale (SURPS).
Study: NCT04785625

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: INL-001 (bupivacaine hydrochloride) implant

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo collagen-matrix implant
Description: Placebo collagen-matrix implant
Study: NCT04646005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered intravenously (IV) every three weeks (Q3W)
Study: NCT05383989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UniVenture Anxiety Sensitivity manual
Description: Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: UniVenture Anxiety Sensitivity manual
Description: Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Anxiety Sensitivity (AS) personality traits on the Substance Use Risk Profile Scale (SURPS).
Study: NCT04646005

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ISA101b
Description: Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
Study: NCT05383989

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: UniVenture Sensation Seeking manual
Description: Intended for those who score at least 0.5 standard deviation (SD) above the population-specific norm on Sensation Seeking (SS) personality traits on the Substance Use Risk Profile Scale (SURPS)
Study: NCT05372965

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental-periodontitis-mirna-223-gingival tissue-saliva samples
Description: Non-surgical periodontal treatment will be applied to individuals with periodontitis, gingival samples will be collected during the treatment, clinical measurements and saliva collection will be repeated 6 weeks after the treatment. MiRNA-223 gene expression analysis will be performed by real-time PCR (Polymerase Chain Reaction) method in saliva and gingival samples of individuals. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control-clinical healthy mirna-223-gingival tissue-saliva samples
Description: Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study. MiRNA-223 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. A pre-treatment saliva sample will be collected from the clinically healthy group. A tissue sample will be collected during the clinical crown lengthening operation.
Study: NCT05844592

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INV-101
Description: subjects will be randomized 3:1 ratio

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INV-101
Description: subjects will be randomized 3:1 ratio

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INV-101
Description: subjects will be randomized 3:1 ratio

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: INV-101
Description: subjects will be randomized 3:1 ratio
Study: NCT04928521

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae plane block with 30 mL 0.25 % bupivacaine
Description: Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 30 mL 0.25 % bupivacaine

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae plane block with 20 mL 0.25 % bupivacaine
Description: Preoperative, awake, bilateral, ultrasound-guided erector spinae plane block with 20 mL 0.25 % bupivacaine
Study: NCT05349292

Intervention type: OTHER
Intervention: ANH
Description: one group will be managed with ANH and the other without (control group)